Archive for the ‘Drug Addiction’ Category

Science and Emotion and Drug Addiction Exposed: A Review of Memoirs of an Addicted Brain: A Neuroscientist Examines His Former Life on Drugs by Dr. Marc Lewis

Sunday, December 4th, 2011

Dr. Marc Lewis’ book, Memoirs of an Addicted Brain: A Neuroscientist Examines His Former Life on Drugs, has only been out a few weeks and already the reviews are rolling in praising the work as a both a literary and a scientific achievement:

Ian Brown of the Globe and Mail calls it a “…picture of addiction as an unavoidable urge of human nature.” Dr. Gaber Maté, author of In the Realm of Hungry Ghosts: Close Encounters with Addiction, notes the book is “…illuminating to experts, accessible to all.” And Dr. Evan Thompson, professor of philosophy at the University of Toronto, claims that “Great writers create new genres, and that’s exactly what Lewis has done.”

Lay audiences and recovering addicts alike agree. Lewis, now a developmental neuroscientist, has presented an autobiographical odyssey that first off, details the “what” and expresses the “how” of the life of an addict who started with booze as a kid and made his way through LSD and opium and heroin. Two, explains the “why” of the addicted brain on alcohol, on psychedelics and psychotropics, and on opiates.

Memoirs of an Addicted Brain is written in four parts with fifteen chapters that tail the major movements and many milestone moments that created the addict:

Part I, The Tabor Chronicles, includes a fifteen-year-old Lewis’ adventures and misadventures (which are not all that aberrant) at a private para-naval academy for boys in New England, hundreds of miles from his home turf in Toronto, Canada. The section outlines the human influences (rich and righteous adolescent bullies, a concerned mother, a proud father, and so on.) and details the personal experiences and emotions (including Lewis’s being “gutted” by depression) that the author implicitly explains contributed in some way to his developing an addiction that lasted most of his life to date.

Part II, Life and Death in California, follows the author’s studies at UC Berkeley and his experiences in the city that in 1968, the year Lewis arrived in San Francisco/Berkeley, were part of the larger movement to make love, drop out, and drop acid—which Lewis did with a frequency and a frenzy that rivaled only his drug-seeking and drug-getting behavior: he played with LSD and mescaline, but tousled with heroin, explaining in his memoirs that by then it had gone beyond depression as a reason for doing drugs and had become a part of his brain’s neurochemical make-up that drove this otherwise hard-working psychology major to want, then, need, then be neurochemically programmed to crave chemicals so badly the solution would become (as he would illustrate in Part IV) to steal them to feed the “cycle of craving” of the addicted brain.

In Part III, Going Places, the opiate family continues to plague the craven, with the great grand-daddy of the family, opium. The first time he had felt the effects of alcohol, as he explains in Part I, he had finally “felt cheerful.”  The first time he had done heroin, Lewis describes in Part II, he had felt the unique feeling that many addicts in recovery now describe as that which is better than sex (as that, which one addict once told me, if God made anything better than He had kept for Himself): as bringing about “a nexus of bodily comfort and emotional well-being. A warm syrup…,” whereby, “There is no sleepiness, no drowsiness…,” a place whereby, “Outside of [him] nothing exist[ed].”  And with opium, as he experienced it throughout his travels with medical teams in Malaysia, Calcutta, and elsewhere throughout Asia, the pleasure as an escape from pain (his depression), it was relief and it was reward that, he narrates, kept him returning for more.

And as he does in most of the chapters of the book, Lewis moves beyond the addict-in-him experiences to the addicted person’s feelings to the addicted brain’s needs. With the opiates, or opioids, for instance, Dr. Lewis differentiates between the natural opioids of the human brain and the synthetic opioids that reproduce the sought-after highs, the highs that are pursued with such tendentiousness, he says, one is “willing to do anything” to get them.

As he writes, natural opioids of the brain’s hypothalamus function in three ways, “to provide relief from pain or stress, to produce a sense of pleasure or well-being that can energize any goal, and to use either or both of these feelings-relief and/or reward-as the emotional currency of human attachment.” What happened for him, and what happens, at the brain level, with opium, then, is a provision of two kinds of feelings, or two ways opium (and opioids) could exorcise his demons of depression and loneliness: by “inhibiting the firing of neurons [found everywhere in the brain, the spinal cord, brain stem, insula, amygdala, etc.] that are activated by pain or stress;” and by “trigger[ing] opioids in the ventral striatum…trigger[ing] dopamine release, enhancing the appeal of whatever’s showing up on the screen of perception….”

As his misadventures by Part IV of the book, In Sickness and in Health, illustrate, such as getting work as a graduate student in a mental institution where in the labs he steals the chemicals/drugs, the feel-good/rewarded/pain relieved feelings neuroscientifically justify the Lewis who went from liking his highs to wanting and even needing these highs to continue and repeat. As he explains in the memoirs, “Natural goodies like food and sex certainly follow the progression from liking to wanting. Feels good—want more. But with goodies both natural and acquired, it is dopamine’s flame of desire, unleashed by the ahhhhh of opioids, that causes animals to repeat behaviours that lead to satisfaction.

The components responsible, the opioid receptors, are so potent in assigning to the human the propensity for drug addiction because, Lewis explains, they are found in a multitude of places, addressing, like his many personal malaises, multileveled forms of suffering with manifold aspects that are psychologically susceptible to opioid relief.

As Dr. Lewis writes in his intro, drugs can teach us a lot about the brain, and what we know about the brain can teach us a lot about addiction.” And as the Psychology Department, University of Oregon’s Professor Don Tucker acclaims, what Dr. Lewis’ book does is “teach…us how normal yearning can be short-circuited by addiction.” Thus, in many ways does Memoirs of an Addicted Brain function as a human-interest chronicling of drug-addicted behavior, as a neuroscientific and biophysical as well as biopsychological guidebook, as an all around good, informative read.

Memoirs of an Addicted Brain: A Neuroscientist Examines his Former Life on Drugs. By Marc Lewis, Ph.D,  320 pp. Doubleday Canada, $21.75
Website: http://www.memoirsofanaddictedbrain.com/
Available at
Amazon, among other retailers.

Adult ADD – linked to Addiction and Substance Abuse

Thursday, September 16th, 2010

Among adult suffers from substance abuse disorder (SUD), adult attention deficit hyperactivity disorder (adult ADHD or ADD) is a common diagnosis with a prevalence of 15-30%. There is mounting evidence that ADHD is an important risk factor in the development and persistence of addiction. ADHD is associated with an early onset of substance abuse, a more rapid transition into severe types of substance abuse and a problematic course of SUD, including more difficulty in reaching remission.

Data on ADHD prevalence in EU countries are scarce. A systematic prevalence study has not yet been executed. Until recently, the majority of ADHD patients would remain undiagnosed due to a lack of recognition of the disorder and lack of treatment expertise. Controlled long term studies of the effect of ADHD treatment on the prognosis of addiction are also still lacking. ICASA increases knowledge and awareness on the subject of ADHD and SUD.
With the launch of the website the International Collaboration on ADHD and Substance Abuse (ICASA) is now an official Foundation. “An important step forward for research on ADHD and Substance Abuse”, says ICASA-director Geurt van de Glind of the Trimbos Institute in the Netherlands. “When Substance Use Disorders develop in people with ADHD, both disorders are complicated even further. Working for ICASA provides the opportunity to conduct important and innovative research with a team of international experts and to contribute to a better understanding of the relationship between these disorders”, states Sharlene Kaye from the National Drug and Alcohol Research Centre, Australia, and board member of ICASA.

ICASA is a collaborative network of over 40 researchers from 11 EU-countries, the USA and Australia. They all share one ambition: to contribute to a substantial decrease in the proportion of ADHD patients developing a Substance Use Disorder (SUD) and to substantially improve the detection, diagnosis and treatment of patients having both ADHD and SUD.

Currently ICASA is conducting three studies: the IASP (International ADHD in Substance use disorders Prevalence) prevalence study; the DNA sampling within the IASP study and the CASP study – Continuous performance test for ADHD in SUD patients. Two further studies are currently being developed: one international study on the genetics of ADHD and Drug Dependence (ISGADD) and another on the effects of physical exercise for patients with ADHD and SUD. This is just the beginning, with many studies to follow in the future. (Courtesy of ICASA)

Adult ADD

It was some 40 years ago that ADHD researchers tracking children over the years began to recognize that the symptoms of ADHD frequently persisted and followed a child into his teen and adult years. Family studies also often demonstrated that parents of children with ADHD frequently had similar problems. Adult ADHD was thus officially accepted in the DSM in 1978, and understood to occur in both children and adults. To differentiate the adult version it was referred to as Adult ADD; as hyperactivity did not play a major role in the adult version, the H (designating hyperactivity) was omitted.

It is estimated that there are close to one million adults in Canada that have Adult ADD. Some healthcare experts feel the problem is far more widespread, and that Adult ADD problems actually afflict twice that many people. Since Adult ADD is a spectrum type affliction there are various degrees of impairment. This can range from suffering from moderate disorganization, to a totally chaotic inability to focus and accomplish even the basics of managing one’s own life. This makes an accurate estimate of the prevelence of Adult ADD difficult to determine.

The Video below is an introduction to a series of videos about Adult ADD. To access the series please watch the introduction and then click onto the next video in the sequence. Videos courtesy of Experts Village.

A list of some of the more common ADHD medications

Amphetamines

  • Adderal (two strengths, one for short period, one for longer periods)
  • Dexedrine (lower dosage – taken several times a day)
Methylphenidate

  • Ritalin
  • Ritalin LA (will last up to 12 hours).
  • Methylin
  • Focalin
  • Focalin XR (will last up to 12 hours)
  • Metadate CD
Others

  • Atomoxetine HCI (Strattera)
  • Bupropion (Wellbutrin XL)
  • Benzphetamine
  • Clonidine
  • Provigil

Video Information on ADHD

Dr. Matthew H. Erdelyi Ph.D, Professor of Psychology at Brooklyn College, on HD, ADD and ADHD. Video courtesy of illumistream Health.

New Report on Canada’s War on Drugs

Friday, April 2nd, 2010

Report from UBC’s Urban Health Research Initiative finds that Canada’s so-called war on drugs has not stopped the supply of drugs in the streets.

According to the new report released in Ottawa last week, our war on drugs has only served to increase drug-related violence.

Authors reviewed international research and concluded that 87% of studies linked strict law enforcement with an increased “drug-market violence”.

Dr. Evan Wood, the reports co-author, said that the “gun violence that we’ve seen in B.C., as in Mexico and the U.S., appears to be directly attributable to drug prohibition.”

He explains that prohibition simply drives up the value of drugs, thus creating an extremely lucrative market.

The report, thus, concludes that drug issues should be addressed as public health issues, and not as law and order, advocating that money should be spent on health measures that have better results than costly law-enforcement that don’t actually address drug addiction.

According to the report, we should be addressed the demand, not the supply.

This is a perspective echoed by the Obama administration and his new drug czar Gil Kerlikowske.

Download the full report here.

Source: The Province

New OxyContin Policies for Manitoba

Monday, March 29th, 2010

According to an official news release from the Health Living, Youth and Seniors Minister Jim Rondeau additional safeguards for the use of OxyContin will soon be placed in Manitoba.

The province is planning “aggressive action on OxyContin misuse”.

This includes moving the prescription drug to part three of the Provincial Drug Program Formulary, which includes an education campaign and funding for training to facilitate an increase in the number of physicians with a methadone license.

The Provincial Drug Program Formulary consists of three parts, each with an increasing number of controls. Moving OxyContin to the third part means the highest level of controls on the prescribing of the drug in addition to the existing controls.

Existing controls include the Manitoba Prescribing Practices Program, which is used to monitor and control the prescription and dispensation of certain restricted drugs.

The education campaign, aimed at patients with OxyContin prescriptions as well as the general public, is currently being developed. Manitoba is looking to increase understanding of the dangers of misuse of the painkiller and will include posters and pamphlets to be distributed to medical clinics and pharmacies around the province.

Furthermore, as part of the Minister’s overall strategy is the increased capacity to provide methadone treatment for OxyContin addiction. This is to include funding for training of physicians in methadone treatment to facilitate the overall increase in the number of physicians who are licensed and trained to administer methadone as part of drug addiction treatment.

Read the official press release here.

US Children are Huffing

Monday, March 22nd, 2010

According to a new study from the US Department of Health and Human Services, inhalants have become the drug of choice.

According to the study, using data collected from 2006-08 surveys on drug use and health, more 12-year olds admit to using inhalants to get high than prescription medications, marijuana, cocaine and hallucinogens. Alcohol, on other hand, is the only other substance used more among the age group.

Huffing is the act of inhaling vapours to get high. Children huff such common household products as gasoline, nail polish, bleach, paint solvents, and cleaning sprays making it a difficult problem to combat.

Huffing can cause cardiac arrest, lead to brain, heart, liver kidney damage, and addiction.

The recent survey revealed that about 7 percent of 12-year olds used inhalants to get high, compared to 5 percent who used prescription medications, 1.4 percent who used marijuana, and less than 1 percent who used cocaine and hallucinogens.

The percentage of youth using inhalants has remained steady over recent years.

There is also a perception, experts say, that they are not dangerous to use. According to the National Institute on Drug Abuse, from 2001 to 2009 the number of 8th graders who believed inhalants were risky dropped from 75 percent to 58 percent.

A dangerous trend, they say, as where there is a lower perception of risk, there is increased use.

Consequently, inhalants will be the target of a new public education campaign, aimed at youth and their parents.

Source: The National Post

Methadone Treatments

Thursday, March 4th, 2010

We are really proud to announce the launch of our first ever microsite!

Explaining our Methadone Treatments–from Methadone Therapy and Methadone Maintenance, to our Methadone Reduction Program–our new microsite is packed with information.

Are you or your loved one considering methadone as part of their drug addiction treatment? If so, make sure to peruse the site and call us to discuss any of your questions or concerns.

Anxiety Drug Addiction Explained by New Research

Wednesday, February 24th, 2010

New research explains how addiction to prescription anxiety medication works, and may lead to development non-addictive versions of the drugs.

Scientists from the US and Switzerland have discovered how anxiety medications, such benzodiazepine drugs as Ativan, Xanax, and Valium, work in the brain. As it turns out, the drugs use the same reward pathways as heroin and cannabis—pathways that may lead to addiction.

The calming effects of benzos are due to an increased activity of the neurotransmitter GABA (gamma-aminobutyric acid). This in turn activates dopamine, the ‘gratification hormone’, resulting in a reward pathway in the brain.

Reward pathways are both naturally occurring and already exist in the brain. They are an evolutionary mechanism that was essential to our survival. Their main function is to make us feel pleasure when we engage in behaviours central to survival—such as eating or sex.

Opioids, such as heroin, and cannabis work in the same fashion. And dopamine, as we know from new research earlier this month, is directly linked to a propensity for addiction.

Researchers behind the study, published in the journal Nature, say these findings may lead to non-addictive alternative benzodiazepines. Benzos work by binding to a specific part of the GABA, the alpha 1 sub-unit of GABA type A receptor according to scientists. Developing similar drugs that bind to a different part of the GABA may offer the same benefits and calming-effects without the addictive side effects.

Drug companies for quite some time have been trying to develop a new generation of benzos with very little success. This, however, could be the breakthrough needed.

Source: Reuters

Hormone Dopamine Linked to Addiction and Risk-Taking

Monday, February 15th, 2010

New research on dopamine and dopamine receptor profiles could lead to new drug addiction prevention and treatments.

Japanese and Danish scientists have shown in new research that those with higher dopamine levels in the brain have a greater need for stimulation, due in part to the lowered dopamine-sensitivity.

Dopamine is the “gratification” hormone, widely known to relate to the physiology of addiction. Previous research has discovered that drug addictions such as cocaine addiction work by causing a build-up of dopamine in the brain. This build up, in turn, causes a lower sensitivity to the neurotransmitter.

However, according to the new research, it is the naturally occurring higher levels of dopamine in the brain that can lead to addictive behaviours. Dopamine levels can indicate a natural predisposition to risk-taking, and addiction.

Dopamine has been connected to both behaviours—each involve chasing a high, whether naturally induced or chemically. As well, drug addiction can be classified as a high-risk behaviour. Studies have shown that sensation seeking, the constant need for stimulation, and drug or alcohol abuse involves the same reward system in the brain.

Higher levels of dopamine, and lower sensitivity to the hormone, leads to greater risk-taking—and thus greater chance of addiction to drugs, gambling, and more.

Lead by Albert Gjedde of Copenhagen University, researchers used brain scans of volunteers to measure dopamine and dopamine receptor levels. Those on the higher end of the dopamine scale felt less affects from the same amount of the hormone than those on the lower end of the scale.

They also discovered that those who fell on opposite ends of the scale had significantly different dopamine and dopamine receptor profiles.

Their research suggests that it could be more effective to increase or decrease dopamine levels, rather than try to block dopamine receptors in the brain, to treat drug addiction. These findings could help to develop new ways to prevent and treat addiction.

Source: The National Post

Cocaine Addiction: Gene Alterations From Prolonged Cocaine Use

Monday, January 18th, 2010

US Researchers at NIDA report having identified a key brain mechanism, better explaining how and why cocaine addiction occurs.

Announced last week, January 7th 2009, government scientists at the National Institute on Drug Abuse (NIDA) said that the new discoveries about the root of cocaine addiction could lead to the development of new drug treatments.

In experiments with mice, scientists showed how cocaine affects the epigenetic process histone methylation. Prolonged cocaine use, they found, can cause permanent changes to the way certain genes turn on and off.

Epigenetic is a process that influences a gene’s expression or appearance without changing the underlying DNA sequence, causing the gene to behave, or express, itself differently.

Histone methylation is the modification of certain amino acids in a histone protein, or the protein around which a DNA strand wind, which essentially turns the DNA off.

Cocaine in the brain prevents the enzyme from shutting off genes in the pleasure circuits of the brain, heightening cravings for more cocaine.

Furthermore, scientists were able to reverse the effects by increasing the activity of that particular gene, completely reversing the effects of chronic cocaine use. As well, scientists reported that it is likely that this be the same process for other addictions, including alcohol addiction, thereby potentially leading to new, more effective, addiction treatments.

“This fundamental discovery advances our understanding of how cocaine addiction works,” Dr. Nora D. Volkow, director of NIDA, said via press release. “Although more research will be required, these findings have identified a key new player in the molecular cascade triggered by repeated cocaine exposure, and thus a potential novel target for the development of addiction medications.”

The findings also help to explain addiction’s long-term cravings and relapse despite periods of total abstinence.

Source: Business Week & Ottawa Citizen

New Cocaine Addiction Treatment on the Horizon: A Bacterial Enzyme

Wednesday, January 6th, 2010

Researchers in the UK have identified a bacterial enzyme that, they say, breaks cocaine down in the body, effectively reducing the drug’s addictiveness and may help fight both cocaine addiction and overdose.

The naturally occurring bacterial enzyme, Cocaine esterase or CocE, essentially breaks cocaine molecules down in the body, reducing its physical addictiveness and eventually lead to a new way to treat cocaine addiction, as well as help reduce cocaine overdose.

CocE, researchers found, is only active in the body for a rather short period of time. However, they have also found a more stable version in a double mutant bacterial version, DM CocE.

In their clinical trial, published in the Journal of Pharmacology and Experimental Therapeutics, researchers from The Scripps Research Institute trained rats to self-administer cocaine. By pressing a button, cocaine would be released to the rats, mimicking human drug-seeking behaviour common to all addictions.

Once given the double mutant bacterial enzyme, the rats pressed the cocaine-administering button far less, suggesting that the enzyme successfully broke the cocaine down and rendered it far less physically addictive.

Lead researcher told reporters that although the enzyme is not a fail-safe cure for “determined users”, it could nonetheless prove to be a new effective therapeutic approach.

As with all medical interventions to treat addiction, this new treatment should be used in conjunction with a therapeutic drug addiction treatment program.

However, unlike others, it seems at first to have far less harmful side effects and be less addictive in the long term, and could very well prove to be an exciting development in the treatment of cocaine addiction.

Source: The Telegraph